All In Biotech

Drug Trial Radar · NCT06831370

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

124

Planned (sponsor's estimate)

Start

Aug 28, 2024

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. All participants will receive brentuximab vedotin plus AVD for approximately 6 months. Participants will undergo tests like Echocardiography (ECHO) and pulmonary function testing (PFT) during the study. ECHO is a test that uses ultrasound to show how the heart muscle and valves are working; PFT is a test to check how well a participant's lungs work. Each participant will undergo a final health status check 2 months after the last treatment with brentuximab vedotin plus AVD.

Conditions

  • Hodgkin Lymphoma

Interventions

  • Brentuximab VedotinDrug

    Brentuximab Vedotin IV infusion

  • DoxorubicinDrug

    Doxorubicin IV infusion

  • VinblastineDrug

    Vinblastine IV infusion

  • DacarbazineDrug

    Dacarbazine IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), and Unexpected ADRsTime frame: Up to 40 weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • AIIMS

    New Delhi, India · Recruiting

  • HCG City Cancer Centre

    Vijayawada, Andhra Pradesh, India · Recruiting

  • Gauhati Medical college and Hospital

    Guwahati, Assam, India · Active not recruiting

  • Unique Hospital Multispeciality and Research Institute

    Surat, Gujarat, India · Recruiting

  • HCG Cancer Centre

    Bangalore, Karnataka, India · Recruiting

  • JIPMER

    Puducherry, Kerala, India · Active not recruiting

  • HCG Manavata Cancer Centre

    Nashik, Maharashtra, India · Active not recruiting

  • ACTREC

    Navi Mumbai, Maharashtra, India · Active not recruiting

  • DMH

    Pune, Maharashtra, India · Active not recruiting

  • Rajiv Gandhi Cancer Hospital

    Delhi, New Delhi, India · Active not recruiting

  • NRS Medical college & Hospital, Kolkata

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.